From: Personalizing health care: feasibility and future implications
Disease area | Host genotype | Treatment | References |
---|---|---|---|
Optimizing drug efficacy | Â | Â | Â |
Chronic hepatitis C | IL28B | Pegylated interferon alpha, Ribavirin | |
Breast cancer, other tumors | Â | Anthracyclines, poly(adenosine diphosphate-ribose) polymerase inhibition | |
Preventing drug toxicities | Â | Â | Â |
HIV type 1 | (HLA)-B*5701 | Abacavir | |
Rheumatic and inflammatory bowel disorders | Thiopurine methyl transferase genotypes | Azathioprine | |
HLA-B*58:01 | Allopurinol | ||
Gastrointestinal cancers | Dehydropyrimidine dehydrogenase deficiency | 5-fluorouracil | [136] |
UGT1A1 polymorphism | Irinotecan | [137] |